VITTIA
DEFESA E NUTRIÇÃO

EARNINGS RELEASE
4Q25

São Joaquim da Barra, March 12, 2026. Vittia S.A. (VITT3: BZ) ("**Vittia**" or "**Company**"), a Brazilian company specialized in biotechnology (biopesticides and inoculants) and special plant nutrition with solutions for several agricultural crops, announces its results for the fourth quarter of 2025 ("**4Q25**") and fiscal year ended December 31, 2025 ("**2025**").

Our Business

By the end of 2024, we operated in four product divisions: Foliar Fertilizers and Industrial Products; Soil Micronutrients; Soil Conditioners and Organominerals; and Biological Products. In 1Q25, Vittia adopted a new approach to segmenting operating results as part of a strategic reorganization aimed at providing greater clarity on the performance of its main product lines and aligning its reporting structure with international market trends and the industry's most widely adopted practices. As a result, the reportable segments are now classified as: (i) Soil Fertilizers; (ii) Foliar Fertilizers and Industrial Products; and (iii) Biological and Natural Solutions.

It is important to highlight that the change in reportable segments had no impact on comparative information, since the data from the previous year were reclassified based on the new structure, enabling an adequate and consistent comparison between the periods presented.

These divisions share a centralized administration, composed of the same administrative center, including the Board of Directors and Advisory Committees, Management, Operating and Control Systems, Technology, and People, among others. We have specialized and qualified teams committed to delivering high-quality, differentiated products to continuously meet market demands, with a focus on superior productivity, financial performance, and alignment with an ESG matrix.



4Q25 Highlights

Cash generation from operating activities of **R$ 110.5** million in 2025, 69.6% growth, resulting in net debt of **R$ 125.6** million and leverage of **1.09x** Adjusted EBITDA

Net revenue totaled **R$ 258.1** million in 4Q25 (**+0.9%** vs 4Q24) and **R$ 820.0** million in 2025 (**+4.2%** vs. 2024)

43.2% growth in the Soil Fertilizers segment in 2025 (vs. 2024)

Adjusted EBITDA totaled **R$ 45.6** million in 4Q25 (**-25.6%** vs. 4Q24) and **R$ 115.2** million in 2025 (**-13.6%** vs. 2024)

The adjusted net result was negative by **R$ 32.1** million in 4Q25 (**-30.8%** vs. 4Q24) and **R$ 60.2** million in 2025 (**-20.0%** vs. 2024)

Payment of **R$ 50.5** million between buyback and JCP in 2025

Launch of sales at **Vittia México**, with **12 active registrations** in the portfolio

Launch of 2 insecticides and 1 fungicide: **Meta-Turbo Max**, **Bovéria-Turbo WP** and **Tricho-Turbo OD**

Message from Management

The fourth quarter of 2025 marked the end of another challenging year for Brazilian agribusiness. Although weather conditions remained favorable and the outlook for the 2025/26 crop season remains positive, the sector remained under pressure from tighter margins, higher financing costs, and more restrictive credit conditions. In this context, greater rationality in purchasing decisions across the agricultural input supply chain became even more evident, reinforcing the importance of operational discipline, efficient capital management, and close relationships with producers as key pillars of competitiveness.

It was in this environment that Vittia once again demonstrated the resilience of its business model and the consistency of its strategy. In 2025, the Company recorded a 4.2% growth in Net Revenue compared to the previous year, with particular emphasis on the performance of the Soil Fertilizers segment, whose revenue reached R$ 79.0 million in 4Q25, an increase of 72.8% compared to 4Q24. For the full year, this line totaled R$ 263.6 million, a growth of 42.2%, reinforcing the assertiveness of our portfolio strategy and the Company's ability to adapt to a more selective scenario.

The efficiency agenda also continued to advance consistently. In 2025, Selling, General and Administrative expenses (SG&A) increased by 1.3% year over year, reflecting disciplined execution, cost rationalization, and a constant focus on productivity. At the same time, we maintained solid operating cash generation and a balanced capital structure, closing the year with Adjusted EBITDA of R$ 115.2 million and leverage of 1.09x Net Debt / Adjusted EBITDA. This represents a comfortable level, supported by efficient working capital management, the quality of our client portfolio, and strict control over delinquency. In line with our capital allocation discipline and commitment to value creation, we returned R$ 50.5 million to shareholders during the period, of which R$ 33.8 million was distributed through dividends and interest on equity, and R$ 16.7 million was allocated to the share buyback program.

Innovation remains a central element of our growth and differentiation strategy. In an environment of tighter demand from customers, the relevance of solutions that deliver proven agronomic results and clear economic returns for farmers becomes even greater. For this reason, we continue to invest consistently in Research, Development and Innovation, focusing on expanding our pipeline and advancing the technological development of our portfolio. In 2025, we reformulated the products META-TURBO MAX, BOVÉRIA-TURBO WP, and TRICHO-TURBO OD, incorporating exclusive and more efficient strains. We also recorded excellent commercial acceptance and agronomic performance of Triunfe in its first crop season, reinforcing our confidence in the potential of this technology. These advances, concentrated in the Biological and Natural Solutions line, reaffirm Vittia's technological leadership and its contribution to a more productive, efficient, and sustainable agriculture.

The year 2026 also represents an important milestone in the Company's trajectory, as it celebrates 55 years of operations in Brazilian agribusiness. Since its origins in the biological inoculants segment, Vittia has built a history grounded in technical knowledge, innovation, and long-standing relationships with farmers. In this context, we launched our new institutional positioning, "My roots, new stories," an expression that captures the Company's historical connection with the field and reaffirms the foundation upon which we continue to build the future: trust, consistency, and a long-term commitment to customers, partners, and distribution channels.

We remain confident in the medium and long-term prospects for the sector. The gradual normalization of agribusiness conditions, combined with structural drivers such as the transition toward more sustainable agriculture and the ongoing pursuit of productivity, efficiency, and profitability, should continue to create meaningful growth opportunities. With a diversified portfolio, financial discipline, and strong innovation capabilities, Vittia remains well positioned to capture these opportunities and continue generating value in a sustainable manner.

Economic and Financial Performance

In thousands of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Net revenue	**258,149**	**255,788**	**0.9%**	**819,983**	**786,619**	**4.2%**
Cost of goods sold	(175,438)	(161,487)	8.6%	(576,342)	(520,828)	10.7%
Gross profit	**82,712**	**94,301**	**(12.3%)**	**243,641**	**265,791**	**(8.3%)**
Gross margin	32.0%	36.9%	-4.8 p.p.	29.7%	33.8%	-4.1 p.p.
Operating expenses (i)	**(26,779)**	**(46,251)**	**(42.1%)**	**(171,183)**	**(177,549)**	**(3.6%)**
Adjusted EBITDA	**45,640**	**61,338**	**(25.6%)**	**115,223**	**133.283**	**(13.6%)**
Adjusted EBITDA margin	17.7%	24.0%	-6.3 p.p,	14.1%	16.9%	-2.9 p.p,
Net financial result	**2,397**	**2,286**	**4.8%**	**350**	**4,723**	**(92.6%)**
Income tax and social contribution	(8,471)	(3,966)	113.6%	(6,657)	(17,663)	(62.3%)
Net result	**49,859**	**46,370**	**7.5%**	**66,151**	**75,303**	**(12.2%)**
Net margin	19.3%	18.1%	1.2 p.p.	8.1%	9.6%	-1.5 p.p.
Adjusted Net result (ii)	**32,067**	**46,370**	**(30.8%)**	**60,222**	**75,303**	**(20.0%)**
Net margin	12.4%	18.1%	-5.7 p.p.	7.3%	9.6%	-2.3 p.p.
Investments (fixed and intangible assets)	**8,640**	**6,035**	**43.2%**	**33,162**	**32,600**	**1.7%**

(i) The adjustment resulting from the decommissioning of the Vittia Organo S.A. manufacturing unit and the late recovery of taxes can be seen in the table "Sales, general and administrative expenses (SG&A)".

(ii) The adjusted net result excludes the accounting impacts related to the decommissioning of the Vittia Organo S.A. industrial unit, located in Patos de Minas/MG, as well as the late recovery of taxes, both values being considered net of the corresponding tax effects.

Operating income

Net operating income by segment

In thousands of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Soil fertilizers	79,002	45,219	74.7%	263,569	184,090	43.2%
Foliar fertilizers and industrial products	86,277	106,546	(19.0%)	281,063	320,837	(12.4%)
Biological and natural solutions	92,870	104,022	(10.7%)	275,351	281,692	(2.3%)
Net revenue	**258,149**	**255,787**	**0.9%**	**819,983**	**786,619**	**4.2%**

Geographic breakdown

Vittia is present throughout Brazil and abroad, with revenue broken down as follows:

Breakdown of net revenue per region (R$ million)



Gross profit and gross margin

In thousands of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Soil fertilizers	**8,918**	**(5,470)**	**N/A**	**22,530**	**4,702**	**379.2%**
Gross margin	11.3%	-12.1%	23.4 p.p.	8.5%	2.6%	5.9 p.p.
Foliar fertilizers and industrial products	**20,882**	**30,129**	**(30.7%)**	**59,738**	**82,685**	**(27.8%)**
Gross margin	24.2%	28.3%	-4.1 p.p.	21.3%	25.8%	-4.5 p.p.
Biological and natural solutions	**52,912**	**69,643**	**(24.0%)**	**161,373**	**178,404**	**(9.5%)**
Gross margin	57.0%	67.0%	-10.0 p.p.	58.6%	63.3%	-4.7 p.p.
Gross profit	**82,712**	**94,301**	**(12.3%)**	**243,641**	**265,791**	**(8.3%)**
Gross margin	**32.0%**	**36.9%**	**-4.8 p.p.**	**29.7%**	**33.8%**	**-4.1 p.p.**

Selling, general and administrative expenses (SG&A)

In thousands of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Selling expenses	(23,142)	(21,054)	9.9%	(77,376)	(79,735)	(3.0%)
Provision for expected credit losses	(597)	(1,445)	(58.7%)	(987)	(358)	175.7%
General and administrative expenses	(29,322)	(25,925)	13.1%	(105,406)	(100,319)	5.1%
Other operating income (expenses)	26,281	2,173	1109.4%	12,586	2,864	339.5%
Total SG&A expenses	**(26,780)**	**(46,252)**	**(42.1%)**	**(171,183)**	**(177,549)**	**(3.6%)**
Net revenue (%)	*10.4%*	*18.1%*	*-7.7 p.p*	*20.9%*	*22.6%*	*-1.7 p.p*
(+) Unit demobilization (i)	-	-	N/A	15,568	-	N/A
(+) Late recovery of taxes (ii)	(24,296)	-	N/A	(24,296)	-	N/A
Total SG&A excluding demobilization	**(51,076)**	**(46,252)**	**10.4%**	**(179,911)**	**(177,549)**	**1.3%**
Net revenue (%)	*19.8%*	*18.1%*	*1.7 p.p*	*21.9%*	*22.6%*	*-0.6 p.p*

(i) In September 2025, the Company completed the decommissioning of Vittia Organo S.A. manufacturing facility located in Patos de Minas, Minas Gerais as part of its strategic plan to optimize the production structure and concentrate operations in the unit located in Serrana, São Paulo. The decommissioning did not compromise the Company's overall production capacity, since production was distributed among the other manufacturing units. The total accounting impact associated with the decommissioning amounted to R$ 15.6 million and was fully recognized in the Company's results for the fiscal year.

(ii) In 2025, the company reviewed its tax records from April 2021 to March 2025 and identified late tax credits of R$ 24,296 thousand relating to previous years.

SG&A totaled R$ 179.9 million in 2025, representing 21.9% of net revenue, a 0.6 p.p. decrease compared to 2024. This result reflects the cost rationalization and optimization initiatives undertaken in the previous fiscal year, the effects of which continued throughout 2025. The Company remains focused on its operational efficiency strategy, preserving its commercial capacity and sustaining its growth.

Adjusted EBITDA and Adjusted EBITDA Margin

The Company's adjusted EBITDA (excluding the adjustment to the present value of accounts receivable and non-recurring events) was R$ 115.2 million in 2025 (-13.6% vs. 2024), with an adjusted EBITDA margin of 14.1% (-2.9 p.p. vs. 2024), mainly due to the reduction in gross profit.

Adjusted EBITDA Performance (R$ million)



Adjusted EBITDA margin performance

(1) SGA = General, administrative, other and non-recurring expenses / AFDA = Allowance for Doubtful Accounts / D&A = Depreciation and amortization / PVA = Present value adjustment

Reconciliation of net income and adjusted EBITDA

In thousands of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Net result	49,859	46,370	7.5%	66,151	75,303	(12.2%)
(+) Income tax and social contribution	8,471	3,966	113.6%	6,657	17,663	(62.3%)
(+) Net financial income (loss)	(2,397)	(2,286)	4.8%	(350)	(4,723)	(92.6%)
(+) Depreciation and amortization	6,150	5,679	8.3%	25,121	21,907	14.7%
EBITDA (i)	**62,083**	**53,729**	**15.5%**	**97,579**	**110,150**	**(11.4%)**
EBITDA Margin (i)	*24.0%*	*21.0%*	*3.0 p.p*	*11.9%*	*14.0%*	*-2.1 p.p*
(+) Present value adjustment – PVA	7,853	7,609	3.2%	26,372	23,133	14.0%
(+) Unit demobilization (ii)	-	-	N/A	15,568	-	N/A
(+) Late recovery of taxes (iii)	(24,296)	-	-	(24,296)	-	-
Adjusted EBITDA (ii)	**45,640**	**61,338**	**(25.6%)**	**115,223**	**133,283**	**(13.6%)**
Adjusted EBITDA margin (i)	*17.7%*	*24.0%*	*-6.3 p.p*	*14.1%*	*16.9%*	*-2.9 p.p*

(i): EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-accounting measure disclosed by the Company under CMV Instruction 527 of October 4, 2012 ("CMV Instruction 527"), reconciled with its financial statements, and consists of net income plus net financial result, income tax and social contribution expenses, and depreciation and amortization expenses and costs. The EBITDA margin is calculated by dividing EBITDA by the net operating income.

(ii) In September 2025, the Company completed the decommissioning process of the Vittia Organo S.A. manufacturing unit located in Patos de Minas/MG, in line with the strategic plan to optimize the production structure and concentrate operations in the units located in Serrana/SP. The decommissioning did not compromise the Company's overall production capacity, since production was redistributed among the other manufacturing units. The total accounting effect resulting from the decommissioning amounted to R$ 15,568 thousand, which was fully recognized in the results of the fiscal year.

(iii) In 2025, the company reviewed its tax records from April 2021 to March 2025 and identified overdue tax credits of R$ 24,296 thousand relating to previous fiscal years.

Financial result

In thousands of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Interest income and discounts	770	1,291	(40.4%)	2,599	2,914	(10.8%)
Present value adjustment (i)	7,901	6,542	20.8%	25,967	22,541	15.2%
Income from financial investments	1,284	681	88.5%	4,547	3,126	45.5%
Interest expenses	(6,296)	(3,660)	72.0%	(23,426)	(15,770)	48.5%
Discounts granted	(622)	(1,064)	(41.5%)	(1,943)	(2,096)	(7.3%)
Interest on right of use	(919)	(677)	35.7%	(3,028)	(2,783)	8.8%
Tax on financial transactions (IOF) and other	896	(422)	N/A	(292)	(784)	(62.8%)
Exchange variation, net (ii)	(1,274)	(5,350)	(76.2%)	7,230	(10,874)	N/A
Gains (losses) with derivatives (ii)	657	4,945	(86.7%)	(11,304)	8,450	N/A
Net financial result	**2,397**	**2,286**	**4.9%**	**350**	**4,722**	**(92.6%)**

(i) The Present Value Adjustment (PVA), which includes our sales realized in the "Crop Period". In this procedure, the "Accounts Receivable" resulting from such sales are adjusted to their present value through discounts that consider pre-fixed embedded interest. To bring the "Accounts Receivable" to present value we use the average weighted funding cost. This practice has the following impact on our balance sheet and results: in the first moment, the PVA is deducted from our "Accounts Receivable" through an account that reduces the balance sheet, while gross revenue is also deducted at the same amount. With time, the amount deducted is accrued in the financial result under interest gains, reducing the value of the account that reduces the "Accounts Receivable". The monthly accrual is based on the rate used for the discount at the initial moment. Accordingly, upon payment, the value of "Accounts Receivable" is offset by fully debiting the cash account, and the total gross revenue arising from the sale in installments will be partially accrued as operating income upon delivery of the good and partially accrued every month as financial revenue until the payment is made

(ii) To protect itself against risks from exchange rate variations, the Company uses derivative hedging instruments, mainly foreign exchange swaps and NDFs (non deliverable forwards). NDFs are generally used to manage currency exposure on balance sheets, avoiding or minimizing the mismatch on accounts receivable, operating liabilities, and accounts payable that are denominated in dollars. Swaps are usually contracted through operations known as "4131 swaps". In these operations, the Company contracts a debt instrument in foreign currency (Dollar or Euro) with a financial institution, while contracting, at the same time, a swap operation, exchanging this obligation in foreign currency (long end for the Company) for yields based on the variation of Interbank Deposit Certificates – CDI, plus a spread (short end for the Company). These operations are carried out with the same counterparty and with the same amounts and maturity dates. Swaps are classified as fair value derivatives and their results are accounted for as gains (losses) on derivatives. Foreign currency debt is classified under loans and financing, with the result from the exchange variation and interest accounted for as financial expenses.

The net financial result in 4Q25 was R$ 2.4 million (+4.9% vs. 4Q24). In 2025, the result was R$ 0.4 million (-92.6% vs. 2024). The variation in the result for the period is mainly attributed to the increase in average net debt in 2025 (+17.8% compared to 2024) and the increase in the interest rate in the same period, resulting in higher financial charges.

Cash flow management and indebtedness

Cash flow management

Cash flow (R$ million)



In Thousand of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Cash Generation	**(28,066)**	**(5,371)**	**422.5%**	**(6,510)**	**(28,356)**	**(77.0%)**
Operating activities	4,592	(20,073)	N/A	110,508	65,157	69.6%
Investments	(8,529)	(5,507)	54.9%	(31,884)	(31,270)	2.0%
Financing	(24,129)	20,209	N/A	(85,134)	(62,243)	36.8%
Cash and cash equivalents at beginning of period	76,029	59,844	27.0%	54,473	82,829	(34.2%)
Cash and cash equivalents at end of period	47,963	54,473	(12.0%)	47,963	54,473	(12.0%)

The cash variation in 2025 was negative by R$ 6.5 million due to the amortization of financing, which reached R$ 85.1 million (+36.8% vs. 2024) and investments, which totaled R$ 31.9 million (+2.0% vs. 2024), partially offset by operating activities, which totaled R$ 110.5 million (+69.6% vs. 2024).

Indebtedness

The Company's gross debt reached R$ 173.6 million in 9M25 (-13.0% vs. 2024), while net debt registered R$ 125.6 million (-13.4% vs. 2024). The net debt/EBITDA ratio came to 1.09x.

In thousands of R$, except %	2025	2024	Chg. %
Loans and financing (current)	124,930	132,058	(5.4%)
Loans and financing (non-current)	48,627	67,440	(27.9%)
Gross debt	**173,557**	**199,498**	**(13.0%)**
(-) Cash and cash equivalents	(47,963)	(54,473)	(12.0%)
Net debt (i)	**125,594**	**145,025**	**(13.4%)**
LTM Adjusted EBITDA	*115,223*	*133,283*	*(13.6%)*
Net Debt/LTM EBITDA	**1.09x**	**1.09x**	**0.00x**

CAPEX and Research, Development and Innovation

Investments in CAPEX reached R$ 33.2 million in 2025 (+1.7% vs. 2024). These CAPEX investments are primarily focused on operational improvements that can generate productivity gains and cost reductions, without focusing on large-scale projects. The most significant investment this year is the plant to support the launch and growth of Triunfe. The CAPEX strategy seeks to adapt to the current moment of increased conservatism in agribusiness and rising interest rates in the country, seeking the efficient allocation of capital.

Fertilizer and Atypical Pesticides Plant

Vittia's investments in the concentrated suspension line to support the launch of Triunfe, where R$ 6.3 million was invested in 2025. This investment is being used to build a new concentrated suspension line and adapt the layout of the bottling area. Located in São Joaquim da Barra/SP, this plant aims to increase annual production capacity to 4.5 million liters of concentrated suspension products.

R&D Investments

The Company generates value through integrated teams, combining knowledge and experience from the areas of R&DI, Market Development and Regulatory Affairs. At the end of 4Q25, we had 42 R&DI professionals, 25 of whom were exclusively dedicated to this area.

In 2025, the Company invested R$ 27.5 million in research and development, which represents a 6.5% reduction compared to the same period of the previous year. This variation reflects, in part, a lower intensity of field studies in the period, influenced by the readjustment of the technical support structure in the field. This amount corresponds to 3.3% of the Company's net revenue (-0.4 p.p. vs. 2024). It is worth noting the seasonal nature of Capex investments, which does not indicate a reduction in investments by the Company in 2025.

Research and Development Investments

In thousand of R$	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Biological products	5,482	5,645	(2.9%)	20,876	21,625	(3.5%)
Fertilizers	1,672	2,337	(28.5%)	6,573	7,720	(14.9%)
Total	**7,154**	**7,982**	**(10.4%)**	**27,449**	**29,345**	**(6.5%)**
Capex	365	768	(52.5%)	1,067	2,399	(55.5%)
Opex	6,789	7,214	(5.9%)	26,382	26,946	(2.1%)
Net revenue (%)	2.8%	3.1%	-0.3 p.p.	3.3%	3.7%	-0.4 p.p.

Key developments

By the end of 2025, Vittia launched two new high-performance biological insecticides:

- **META-TURBO MAX:** formulated with an exclusive strain, the fungus *Metarhizium anisopliae* BV12 and a unique formulation in a concentrated suspension obtained through liquid fermentation. Its main advantages include high virulence and proven efficacy in controlling pests such as sugarcane boll weevils, fall armyworms, false loopers, boll weevils, brown stink bugs, and coffee leaf miners. The product protects the pests' natural enemies and reduces the likelihood of resistant pests emerging.

• **BOVERIA-TURBO WP:** this is a microbiological insecticide and acaricide formulated with the exclusive BVF15 isolate of the fungus *Beauveria bassiana*. Its wettable powder (WP) formulation protects spores from ultraviolet radiation and is easy to mix in a tank. Indicated for the control of whitefly, coffee borer, sugarcane boll weevil, and corn leafhopper, the product stands out for its rapid action, with insect colonization within 72 hours and high compatibility with the preservation of natural enemies, making it an option for other pest management strategies.

• **TRICHO-TURBO OD:** fungicide developed from the exclusive strain *Trichoderma asperellum* BVF24. The liquid formulation in oil dispersion (OD) protects microorganism spores, ensuring greater virulence in the field. It is widely used to control soil diseases such as wilts and damping-off, as well as nematodes. In addition to its action against pathogens, it favors plant development, promoting greater vigor and productivity.

With these new launches, Vittia strengthens its portfolio of biological solutions and reaffirms its commitment to Brazilian agribusiness, delivering effective, sustainable, and high-performance technologies for controlling major plant pests and diseases. Furthermore, the Company obtained 4 new registrations, 2 new recommendations for biological use/targets, 1 renewal of its Temporary Special Registration (RET) and 3 new Temporary Special Registrations.

The first half of 2025 also marked the start of commercialization for Vittia Mexico, with a portfolio of 12 active registrations in the country.

Human Resources

We ended 4Q25 with 1,110 employees, compared to 1,120 in the previous quarter (-0.9% vs. 3Q25 and -5.2% vs. 2024). All our employees, including those under temporary employment contracts, are directly hired by the Company under the Brazilian Consolidation of Labor Laws (CLT).

The Company maintains a close relationship with the unions that represent its employees. Collective agreements and conventions, as well as those negotiated directly, have a usual duration of 12 months. Vittia also complies with applicable labor laws and conditions established in collective bargaining agreements signed with labor unions, applying them equally to unionized and non-unionized employees.

Capital Markets

The shares of Vittia S.A. (B3: VITT3) have been traded since the IPO, on September 1, 2021, in the Novo Mercado segment of B3, the highest Corporate Governance level in the Brazilian stock market. The Company is also included in the IGC (Special Corporate Governance Stock Index), IGC-NM (Novo Mercado Corporate Governance Equity Index), and ITAG (Special Tag-Along Stock Index) indexes.

Share capital: Vittia's share capital was constituted, on 12/31/2025, by 147.3 million common shares (ON), of which 65.1% belonged to controlling shareholders, 2.6% to the Company's management, 31.9% were in free circulation on the market ("free float") and 0.4% were shares held in treasury.

Market cap: At the end of the quarter, VITT3 share was priced at R$ 4.57, representing a market cap of R$ 686.9 million, compared to R$ 760.6 million at the end of the previous quarter, an decrease of 9.7% or R$ 73.7 million.

Free-float Breakdown: At the end of 4Q25, the free float was distributed as follows: individual investors held 10.4% (vs. 10.1% in 3Q25), local institutional investors held 87.8% (vs. 87.6% in 3Q25), and foreign investors held 1.6% (vs. 2.2% in 3Q25).

Number of shareholders: At the end of the quarter, the Company had 4.2 thousand shareholders, compared to 4.3 thousand at the end of 3Q25, reduction of 1.5%.

Average Daily Trading Volume ("ADTV"): The average daily trading volume was R$ 0.7 million in 4Q25, compared to R$ 0.8 million in the previous quarter, decrease of R$ 0.1 million or 8.9%.

Dividend distribution: By the end of 2025, the Company had paid R$ 33.8 million in dividends, as JCP, paid on 01/06/2025, 05/16/2025, 08/13/2025 and 09/03/2025.

In the RCA held on July 14, 2025, the declaration of distribution of JCP calculated in the period from January to July 2025 was approved, in the gross amount of R$ 20.8 million (R$ 0.14040135117 per share) based on the shareholding position of July 18, 2025. The first installment, in the amount of R$ 7.0 million (R$ 0.04731352488 per share), was paid on August 13, 2025 and the second installment, in the amount of R$ 6.0 million (R$ 0.04055444989 per share) was paid on 09/03/2025, and the third installment, in the amount of R$ 7.8 million (R$ 0.05253337640) was paid on January 6, 2026.

In a Shareholders' Meeting held on October 29, 2025, the declaration of distribution of Interest on Equity accrued in the period from August to October 2025 was approved, in the gross amount of R$ 9.5 million (R$ 0.06474713761 per share) based on the shareholding position of November 3, 2025. The first installment, in the amount of R$ 4.7 million (R$ 0.03214434305 per share), was paid on January 6, 2026; the second installment, in the amount of R$ 4.8 million (R$ 0.03260279456 per share) will be paid on a date yet to be determined.

Furthermore, at a Board of Directors meeting held on December 17, 2025, the declaration of distribution of Interest on Equity ("JCP") in the total amount of R$ 6.6 million (R$ 0.04514632207 per share) was approved, based on the shareholding position as of November 3, 2025, with a payment date to be determined.

Additionally, at a Board of Directors meeting held on December 30, 2025, the declaration of distribution of Interest on Equity ("JCP") accrued in the period from 1996 to 2005 was approved, in the gross amount of R$ 4.7 million (R$ 0.03225465391 per share), calculated based on the application of the Long-Term Interest Rate (TJLP) pro rata day on the Company's Net Worth on December 31 of each fiscal year, with imputation to the mandatory dividend provided for in article 38 of the Bylaws, pursuant to article 9 of Law No. 9,249/1995 and CVM Resolution No. 143/2022. The aforementioned decision observes the understanding established by the Supreme Federal Court in Topic 1319, which recognized the possibility of deducting, for tax purposes, interest on equity related to previous fiscal years, provided that it was calculated in accordance with the legislation in force at the time and declared in accordance with the applicable legal criteria, thus providing legal certainty to the approved distribution.

Share buyback program: In the first nine months of 2025, the Company repurchased the equivalent of R$ 16.7 million, taking into account shares repurchased under the 4th and 5th Share Buyback Program. At the end of February, the Company had 1,695,536 shares held in treasury.

On October 29, 2025, the Company announced that the Board of Directors approved the 5th Share Buyback Program, with up to 4,500,000 common shares to be acquired, representing, on this date, approximately 9.5% of the outstanding shares issued by the Company, with a maximum term of 12 months.

Furthermore, on October 29, 2025, the Company announced the cancellation of 3,000,000 common shares issued by the Company and held in treasury, acquired under the Company's 4th share buyback program, without reducing the share capital, especially for the purposes of Article 9 and Article 10 of CVM Resolution No. 77, of March 29, 2022 ("CVM Resolution No. 77/22"), against the balances of available profit reserves, excluding the balances of the reserves indicated in item I of paragraph 1 of Article 8 of CVM Resolution No. 77/22. As a result, the Company's share capital was divided into 147,314,018 shares.

Increase in Share Capital with Share Bonus: At a Board of Directors' Meeting (RCA) held on December 30, 2025, Vittia S.A. approved an increase in its share capital through the capitalization of R$151.5 million recorded in profit reserves in the balance sheet as of December 31, 2024, with the resulting bonus share distribution to shareholders. As a result of this transaction, 14,731,402 new common shares will be issued and granted free of charge at a ratio of 10% (10 new shares for every 100 shares held), based on the shareholder position as of April 9, 2026. The shares will begin trading ex-bonus as of April 10, 2026. The bonus shares will be credited to shareholders on April 13, 2026 and will carry the same rights as the existing shares, including full entitlement to dividends and/or interest on shareholders' equity declared with a record date after April 14, 2026.

Basic Financial Statements

Income Statement for the Year – 4Q25 vs. 4Q24 and 2025 vs. 2024

Income Statement (R$ thousand)	4Q25	4Q24	Chg. %	2025	2024	Chg. %
Net revenue	**258,149**	**255,788**	**0.9%**	**819,983**	**786,619**	**4.2%**
Sales costs	(175,438)	(161,487)	8.6%	(576,342)	(520,828)	10.7%
Gross profit	**82,712**	**94,301**	**(12.3%)**	**243,641**	**265,791**	**(8.3%)**
Gross margin	32.0%	36.9%	(13.1%)	29.7%	33.8%	(12.1%)
Selling expenses	(23,142)	(21,054)	9.9%	(77,376)	(79,735)	(3.0%)
Provision for expected credit losses	(597)	(1,445)	(58.7%)	(987)	(358)	175.7%
General and administrative expenses	(29,322)	(25,925)	13.1%	(105,406)	(100,319)	5.1%
Other net operating income (expenses)	26,281	2,173	1109.4%	12,586	2,864	339.5%
SG&A expenses	**(26,779)**	**(46,251)**	**(42.1%)**	**(171,183)**	**(177,549)**	**(3.6%)**
Operating profit	**55,933**	**48,050**	**16.4%**	**72,458**	**88,242**	**(17.9%)**
Financial income	9,497	14,671	(35.3%)	43,407	40,858	6.2%
Financial expenses	(7,100)	(12,385)	(42.7%)	(43,057)	(36,135)	19.2%
Financial result	**2,397**	**2,286**	**4.9%**	**350**	**4,723**	**(92.6%)**
Profit (loss) before income tax and social contribution	**58,330**	**50,336**	**15.9%**	**72,808**	**92,966**	**(21.7%)**
Current and Deferred Income Tax and Social Contribution	(8,471)	(3,966)	113.6%	(6,657)	(17,663)	(62.3%)
Result for the period	**49,859**	**46,370**	**7.5%**	**66,151**	**75,303**	**(12.2%)**
Net margin	19.3%	18.1%	1.2 p.p.	8.1%	9.6%	1.5 p.p.

Cash Flow Statements – 2025 vs. 2024

In thousands of R$, except %	2025	2024
Cash Flow from Operating Activities		
Result for the period	**66,151**	**75,303**
Adjustments for:		
Depreciation and amortization	25,121	21,907
Residual cost of sold/written-off fixed assets	8,964	1,838
Current taxes	3,070	13,309
Deferred taxes	3,587	4,354
Provision for bônus	841	3,571
Provision for commissions	8,906	10,088
Interest and monetary variations on loans and financing	25,925	15,713
Interest on lease liabilities	3,073	2,554
Present value adjustment variation	402	700
Provision for doubtful accounts	987	358
Losses with bad debts	(26,696)	-
Fair value of derivate financial instruments	11,822	(8,450)
Provision for contingencies	133	554
Exchange Variation	(6,864)	10,965
Change in working capital		
Increase in trade receivables	2,042	(35,248)
Increase in inventories	4,579	(6,947)
Increase (decrease) in taxes recoverable	8,842	(3,162)
Increase in advances to suppliers	3,405	(2,709)
(Increase) decrease in other receivables	2,822	(1,865)
Increase (decrease) in suppliers	(985)	(1,552)
Increase (decrease) in payroll and social security charges	(1,707)	352
Increase in taxes and contributions payable	(718)	(3,103)
Increase in advances from customers	980	(605)
Increase in other accounts payable	(6,045)	(1,906)
Cash generated by Operations	**138,637**	**96,019**
Income tax and social contribution paid	(1,699)	(5,748)
Interest paid on lease liabilities	(3,073)	(2,554)
Interest paid on loans and financing	(23,357)	(22,560)
Net cash from operating activities	**110,508**	**65,157**

Cash Flow Statements – 2025 vs. 2024 *(continued)*

Cash flows from investing activities		
Receivables from the sale of fixed assets	1,278	1,330
Investment acquisition	-	-
Acquisition of Investments	-	-
Acquisition of fixed assets	(33,265)	(32,753)
Increase in intangible assets	103	153
Net cash flow used in investing activities	**(31,884)**	**(31,270)**

Cash flows from financing activities		
Loans and financing raised	118,000	223,000
Payment of lease liabilities	(7,182)	(5,885)
Payment of loans and financing	(139,647)	(195,169)
Realized derivative financial instruments	(5,838)	(6,409)
Acquisition of treasury shares	(16,678)	(39,589)
Dividends paid	(33,789)	(38,191)
Net cash flows generated by financing activities	**(85,134)**	**(62,243)**

Increase (decrease) in cash and cash equivalents, net	**(6,510)**	**(28,356)**
Cash and cash equivalents at the beginning of the period	**54,473**	**82,829**
Cash and cash equivalents at the end of the period	**47,963**	**54,473**

Balance Sheet as of December 31, 2025 and December 31, 2024

In thousands of R$, except %	2025	2024
Assets		
Current assets	**575,948**	**590,289**
Cash and cash equivalents	47,963	54,473
Derivative Financial Instruments – Assets	-	4,155
Trade receivables	327,881	337,383
Inventories	156,705	161,284
Taxes recoverable	33,625	14,756
Current tax asset	5,026	7,199
Advances to suppliers	1,084	4,489
Other receivables	3,664	6,550
Non-current assets	**353,998**	**362,889**
Non-current receivables	**14,758**	**21,387**
Trade receivables	1,993	3,066
Taxes recoverable	3,624	5,657
Deferred tax asset	7,690	11,277
Other receivables	1,451	1,387
Permanent	**339,240**	**341,502**
Investments	255	256
Fixed assets	302,120	294,961
Right of use	23,096	31,041
Intangible assets	13,769	15,244
Total assets	**929,946**	**953,178**
Liabilities and equity		
Current liabilities	**217,187**	**221,417**
Suppliers	14,197	15,182
Loans and financing	124,930	132,058
Derivative Financial Instruments	2,784	107
Payroll and social security charges	20,753	21,810
Taxes and contributions payable	3,540	4,258
Current tax liabilities	781	5,164
Advances from customers	6,682	5,702
Dividends to distribute and interest on equity	25,481	22,200
Lease liability	6,956	4,878
Other accounts payable	11,083	10,058
Non-current liabilities	**68,386**	**96,844**
Loans and financing	48,627	67,440
Taxes and contributions payable		
Provision for contingencies	735	602
Lease liability	19,024	28,802
Total equity attributable to controlling shareholders	**644,605**	**634,772**
Non-controlling interests	(232)	145
Total equity	**644,373**	**634,917**
Total liabilities	**285,573**	**318,261**
Total liabilities and equity	**929,946**	**953,178**

VITTIA
DEFESA E NUTRIÇÃO

Investor Relations

Alexandre Del Nero Frizzo – CFO and IRO

Laís Nunes – IR Analyst

ri@vittia.com.br

ri.vittia.com.br